Skip to content
    ACI
    Earnings call· Feb 2026(Q4 FY26)

    Albertsons Companies Q4 FY26 earnings call ACI

    Apr 14, 2026 Source

    Executive summary

    Albertsons Q4 FY26 (Reporting FY25 Results) — Strong Productivity and Shareholder Returns Amidst Pharmacy Headwinds

    Albertsons reported its Q4 FY25 results, delivering better-than-expected adjusted EBITDA and strong shareholder returns, navigating significant pharmacy headwinds and consumer pressure through operational agility and productivity. The company is confident in its FY26 outlook, driven by a $2 billion 3-year productivity program, AI-enabled initiatives, and continued investment in its differentiated growth model focused on personalization and balanced value.

    Highlights

    5

    • Identical sales increased 0.7% in Q4 FY25 despite significant pharmacy headwinds.

    • Adjusted EBITDA reached $903 million in Q4 FY25, exceeding expectations.

    • Returned over $1.8 billion to shareholders in FY25 through share repurchases and dividends.

    • Digital penetration surpassed 10% in Q4 FY25, with 16% digital growth.

    • Loyalty membership grew 12% to over 51 million members in FY25.

    Concerns

    4

    • Pharmacy-related headwinds of approximately 145 basis points impacted Q4 FY25 identical sales, primarily from the Inflation Reduction Act (IRA) and industry shift to generics.

    • Moderation in GLP-1 growth created an incremental 40 basis point headwind to Q4 FY25 identical sales.

    • Units in identical sales remained pressured in lowest income cohorts during Q4 FY25.

    • Egg deflation created a meaningful sales headwind in Q4 FY25, expected to persist into Q1 FY26.

    Guidance & targets

    8
    CategoryTargetConfidence
    Identical sales
    0% to 1%
    high materiality
    High
    Adjusted EBITDA
    $3.85 billion to $3.925 billion
    high materiality
    High
    Adjusted EPS
    $2.22 to $2.32
    high materiality
    High
    Effective income tax rate
    24% to 25%
    medium materiality
    High
    Capital expenditures
    $2 billion to $2.2 billion
    high materiality
    High
    Share repurchase authorization
    $2 billion
    high materiality
    High
    Quarterly dividend
    $0.68 per share
    high materiality
    High
    Productivity program
    $2 billion
    high materiality
    High

    Operational metrics

    22
    Opioid legal settlement
    $774 million
    Q4 FY25

    Proposed nationwide opioid legal settlement framework, recorded during the fourth quarter.

    Share repurchases
    nearly $1.5 billion
    FY25

    Includes the completion of a $750 million accelerated share repurchase program.

    Dividends paid
    $322 million
    FY25

    Part of $1.8 billion capital returned to shareholders.

    Net debt to adjusted EBITDA ratio
    2.24x
    FY25

    Demonstrates strength of balance sheet and capacity to fund growth and return capital.

    Refinanced bonds
    $2.1 billion
    Q4 FY25

    Opportunistically refinanced existing bonds.

    Digital penetration
    surpassed 10%
    Q4 FY25

    New milestone for omnichannel ecosystem.

    First-party digital contribution
    nearly 90%
    Q4 FY25

    Contributed to 16% digital growth.

    Digital order fulfillment speed
    more than half
    Q4 FY25

    Reflects strength of store-based fulfillment model.

    Loyalty membership growth
    12%
    FY25

    To more than 51 million members.

    Loyalty members
    over 51 million
    FY25

    Membership grew 12%.

    Personalized ad pilots conversion lift
    90%
    Q4 FY25

    Validating a clear path to scale personalization.

    Industry food inflation outlook
    around 2%
    FY26

    Company has not been passing through inflation at this rate.

    GLP-1 growth headwind
    40 basis pointincremental
    Q4 FY25

    Headwind to identical sales compared to Q3 outlook, driven by tighter payer criteria and increased direct-to-consumer penetration.

    Pharmacy IRA headwind
    105 basis point
    Q4 FY25

    Headwind to identical sales from IRA pricing and mix pressure.

    Total pharmacy headwind
    145 basis point
    Q4 FY25

    Total headwind to Q4 identical sales expectations from pharmacy dynamics.

    Interest expense
    $141 millionincreased $40 million
    Q4 FY25

    Compared to $101 million last year due to higher borrowings and the extra week.

    Adjusted EBITDA
    $903 million
    Q4 FY25

    Better-than-expected, including impact from 53rd week.

    Adjusted EPS
    $0.48
    Q4 FY25

    Productivity continued to drive fuel for investment and the bottom line.

    Identical sales
    2%
    FY25

    Full year performance.

    Adjusted EBITDA
    $3.9 billion
    FY25

    Full year performance, reflecting resilience and productivity.

    Capital expenditures
    $1.84 billion
    FY25

    Invested to modernize store fleet, advance AI, digital, and technology capabilities, and elevate supply chain.

    Working capital improvement
    improvement
    FY26

    Expected to fund approximately half of the planned share repurchases in FY26.

    Industry KPIs

    9
    MetricValueDetails
    Sg a rateimproved by 2 basis pointsbps
    Gross margin drivers27.2%%
    Fuel gas station economicsnear flat trajectory
    Warehouse store club count94 remodels, 9 openedstores
    Comparable same store sales0.7%%
    E commerce digital sales growth16%%
    Advertising retail media revenue90% lift%
    Private label own brand penetrationfairly flat
    Category level comps and inflation deflationmeaningful sales headwind

    Product announcements

    1
    ProductTypeDetails
    Gatewaylaunch

    Deals & partnerships

    1
    Nationwide opioid litigationProposed nationwide opioid legal settlement framework$774 million9 years

    Provides for a $774 million settlement payable over 9 years, recorded during the fourth quarter. This is a meaningful step toward resolving opioid-related litigation without any admission of wrongdoing or liability.

    Capital programs

    2
    Store Modernization & Expansionunderway
    Period spend: FY25: $1.84 billion (total CapEx); FY26: $2 billion to $2.2 billion (total CapEx)
    Start: Ongoing

    Benefit: Remodeled 94 stores and opened 9 stores in FY25. Planned incremental new stores (up 50% from FY25) and amplified remodels in FY26.

    Investment to modernize the store fleet, refresh asset base for long-term growth, and advance AI, digital, and technology capabilities. Benefits from early remodels expected in H2 FY26.

    Productivity Programlaunched$2 billion
    Period spend: Ratable over 3 years
    Start: FY26

    Benefit: Unlocking efficiencies across labor, store operations, supply chain, merchandising, and global capability centers. Supported by technology agenda and 4 big bets in AI.

    New program, increased from prior $1.5 billion target, building on FY25 execution to strengthen operating model and reinforce ability to grow through all cycles. Bulk of savings expected from SG&A.

    Risks & headwinds

    4
    Pharmacy Headwinds (IRA & GLP-1)Q4 FY25, expected to continue into FY26

    145 basis points headwind to Q4 FY25 identical sales (105 bps from IRA/generics, 40 bps from GLP-1)

    Mitigation: Improving pharmacy stand-alone profitability, increasing operational productivity through expanded central fill, enhanced procurement, and scaling higher-margin services.

    Consumer Pressure (Lower Income Cohorts)Q4 FY25, expected to continue in H1 FY26

    Units in ID sales in Q4 FY25 remained pressured

    Mitigation: Surgical price investments, loyalty-driven promotions, own brand innovation, and data-driven personalization to meet customers where they are across income levels.

    Egg DeflationQ4 FY25, expected to persist into Q1 FY26

    Meaningful sales headwind

    Mitigation: Not explicitly stated, but addressed through overall value proposition and productivity efforts.

    Higher Fuel CostsOngoing

    Included pressures related to transportation and distribution expenses in outlook

    Mitigation: Outlook assumes geopolitical conflict ends in a reasonable period; otherwise, incremental pressure possible.

    What to watch in Q1 FY27

    5

    Identical Sales Trend (ex-IRA)

    Q1 FY26 and throughout FY26
    CurrentQ1 FY26 expected below full-year range (0-1% reported, 1.5-2.5% ex-IRA)
    TargetSequential improvement, likely positive in H2 FY26

    Why it matters

    Indicates underlying business health and effectiveness of strategic initiatives beyond pharmacy headwinds.

    Looking at quarterly cadence, we expect identical sales in the first quarter to track below our full year range, including the IRA and significant ongoing egg deflation. As we move beyond this dynamic, we anticipate a sequential improvement in sales trends throughout the year.

    Q&A highlights

    7

    Can you provide more detail on the $2 billion productivity program, including the split between COGS and SG&A, and how it will be realized?

    The $2 billion productivity program over the next 3 years will be ratable, primarily driven by store operations (including shrinkage and Rx), sourcing, and supply chain. The bulk of the savings is expected to come from the SG&A side of the business, amplified by AI big bets and 'buying better together' initiatives.

    “Yes, we just reset our productivity to $2 billion over the next 3 years. You can think of that ratably over that period of time. And when you look at the big areas that, that comes out of, it's going to be our store operations, including shrinkage and Rx, you're going to see us buying better together. Sourcing, both GNFR and in the admin areas, we expect to see benefit supply chain. So we have amplified our activities in this area materially, and we feel very confident in the delivery of this new productivity target over the next 3 years.”

    asked by Leah Jordan · answered by Sharon McCollam

    2 min read6 chapters

    Detailed Narrative

    01

    Strategic Pillars for Future Growth

    Albertsons is positioning itself to win in a competitive grocery environment by focusing on personalization, leveraging its strong store network for convenience and local relevance. The company's strategy is built on three tightly connected pillars: a winning footprint, a customer-centric experience, and balanced value. This approach aims to optimize return on investment, elevate customer experience, and ensure each store plays a clear role in its local market, ultimately striving to become the most loved grocer.

    02

    Technology and AI Transformation

    The company is implementing AI-driven capabilities across four 'big bets': digital customer experience, merchandising intelligence, labor optimization, and supply chain optimization. These initiatives are long-term structural programs designed to drive growth and expand margins. Examples include AI-driven shopping assistance for higher conversion and larger baskets, automated insights for pricing and assortment, generative AI scheduling for labor efficiency, and the proprietary AI-powered 'Gateway' tool for inventory and replenishment.

    03

    Digital and Loyalty Ecosystem Momentum

    Albertsons' digital and e-commerce business continues to be a strong growth engine, with digital penetration surpassing 10% in Q4 FY25 and 16% digital growth, primarily from its first-party business. The strength of its store-based fulfillment model enables speed and efficiency, with over half of digital orders fulfilled in under 3 hours. The loyalty ecosystem grew 12% to over 51 million members, driving higher lifetime value and omnichannel engagement. The media business is also gaining momentum, with personalized ad pilots showing a 90% lift in conversion and click-through rates.

    04

    Balanced Value Proposition

    The company is focused on delivering a balanced value proposition by surgically investing where it matters most to customers. This includes sharpening key value items and driving own brand penetration, funded through structural margin improvement and productivity, rather than short-term trade-offs. The goal is to protect affordability, sharpen value perception, and use data-driven personalization to meet customers across various income levels, trip types, and missions, reinforcing trust and consistency.

    05

    Pharmacy Performance and Outlook

    Despite top-line pressure from the government-mandated Inflation Reduction Act (IRA) and moderation in GLP-1 growth, Albertsons' pharmacy business delivered improved profitability in Q4 FY25. The company expects continued improvement in the underlying trajectory of the business in FY26, with scripts continuing to grow, supported by immunizations and value-added clinical services. Management remains focused on increasing operational productivity and disciplined management of reimbursement and regulatory headwinds🌐.

    06

    Productivity and Capital Allocation

    Albertsons is scaling its productivity engine with a new $2 billion 3-year program, supported by its technology agenda and AI big bets, building on strong FY25 execution. The company's capital allocation priorities include investing $2 billion to $2.2 billion in capital expenditures in FY26 for new stores, remodels, and technology, maintaining and growing its dividend (increased 13% to $0.68 per share), and opportunistically repurchasing shares, with a refreshed $2 billion authorization over approximately the next 3 years.

    AI-generated summary of the company’s earnings call. Not investment advice.